ADMA Biologics (NASDAQ:ADMA) Shares Gap Down – Here’s What Happened

ADMA Biologics, Inc. (NASDAQ:ADMA)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $15.83, but opened at $14.90. ADMA Biologics shares last traded at $14.43, with a volume of 1,239,191 shares.

Analyst Ratings Changes

A number of brokerages recently commented on ADMA. HC Wainwright raised their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Raymond James increased their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday.

ADMA Biologics Stock Up 5.8 %

The company has a market capitalization of $3.96 billion, a PE ratio of 59.76 and a beta of 0.75. The firm’s 50-day simple moving average is $16.69 and its 200 day simple moving average is $17.98. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

Institutional Investors Weigh In On ADMA Biologics

Institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in ADMA Biologics by 21.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 1,509 shares during the last quarter. New York State Teachers Retirement System purchased a new position in shares of ADMA Biologics in the third quarter valued at $1,821,000. Janney Montgomery Scott LLC acquired a new position in shares of ADMA Biologics during the 3rd quarter worth $1,454,000. Robeco Institutional Asset Management B.V. boosted its position in shares of ADMA Biologics by 61.2% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 179,084 shares of the biotechnology company’s stock worth $3,580,000 after buying an additional 68,000 shares in the last quarter. Finally, Roman Butler Fullerton & Co. boosted its position in shares of ADMA Biologics by 241.6% in the 3rd quarter. Roman Butler Fullerton & Co. now owns 107,626 shares of the biotechnology company’s stock worth $2,151,000 after buying an additional 76,121 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.